DDInter1405 DDInter1628
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of developing febrile neutropenia is less than 20% in many readily used chemotherapy regimens, infections pose risks of hospitalization and mortalities. Due to the relatively short circulating half-life of filgrastim, a 20 kDa PEG moiety was covalently conjugated to the N-terminus of filgrastim (at the methionine residue) to develop longer-acting pegfilgrastim.[A29,A187607] Due to a longer half-life and slower elimination rate than filgrastim
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Pegfilgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mercaptopurine
Mercaptopurine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Pegfilgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mercaptopurine
Mercaptopurine {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Pegfilgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) binds {v} (Gene) RET
RET {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Pegfilgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) downregulates {v} (Gene) PLK4
PLK4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Pegfilgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trifluridine
Trifluridine {u} (Compound) upregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Pegfilgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) downregulates {v} (Gene) DUSP4
DUSP4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Pegfilgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Pegfilgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) upregulates {v} (Gene) KLHL9
KLHL9 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Pegfilgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Pegfilgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) downregulates {v} (Gene) PRAF2
PRAF2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) binds RET (Gene) and RET (Gene) is bound by Ruxolitinib (Compound)
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) downregulates PLK4 (Gene) and PLK4 (Gene) is bound by Ruxolitinib (Compound)
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine and Trifluridine (Compound) upregulates DDB2 (Gene) and DDB2 (Gene) is downregulated by Ruxolitinib (Compound)
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) downregulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Ruxolitinib (Compound)
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is bound by Ruxolitinib (Compound)
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) upregulates KLHL9 (Gene) and KLHL9 (Gene) is upregulated by Ruxolitinib (Compound)
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) downregulates PRAF2 (Gene) and PRAF2 (Gene) is downregulated by Ruxolitinib (Compound)